Skip to main content
SpringerLink
Log in

The Role of Tiotropium Bromide, a Long-Acting Anticholinergic Bronchodilator, in the Management of COPD

  • Review Article
  • Published:
Treatments in Respiratory Medicine

Abstract

Bronchodilator therapy forms the mainstay of treatment for symptomatic patients with COPD. Long-acting bronchodilators, which maintain sustained airway patency over a 24-hour period, represent an advance in therapy. Tiotropium bromide is a new long-acting inhaled anticholinergic agent with superior pharmacodynamic properties compared with the short-acting anticholinergic, ipratropium bromide. Tiotropium bromide has been consistently shown to have a greater impact than ipratropium bromide on clinically important outcome measures such as health status. The mechanisms of clinical benefit with tiotropium bromide are multifactorial, but improved airway function, which enhances lung emptying and allows sustained deflation of over-inflated lungs, appears to explain improvements in dyspnea and exercise endurance in COPD. Inhaled tiotropium bromide therapy has also been associated with reduction in acute exacerbations of COPD as well as reduced hospitalizations. The safety profile of tiotropium bromide is impressive: dry mouth is the most common adverse event and rarely necessitates termination of the drug. No tachyphylaxis to tiotropium bromide has been demonstrated in clinical trials lasting up to 1 year. There is preliminary information that the combination of long-acting anticholinergics and long-acting β2-adrenoceptor agonists provides additive physiological and clinical benefits. According to recent international guidelines, long-acting bronchodilators should be considered early in the management of symptomatic patients with COPD in order to achieve effective symptom alleviation and reduction in activity limitation. Tiotropium bromide, because of its once-daily administration and its established efficacy and tolerability profile, has emerged as an attractive therapeutic option for this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic society recommendations for management of COPD. Can Respir J 2003; 10 Suppl. A: 1A–58A

    Google Scholar 

  2. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ERS/ATS position paper. Eur Respir J 2004; 23: 932–46

    Article  PubMed  CAS  Google Scholar 

  3. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64: 457–64

    Article  PubMed  CAS  Google Scholar 

  4. Pauwels RA, Buist SA, Calverly PMA et al. Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 5: 1256–76

    Google Scholar 

  5. Newton M, O’Donnell De, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121(4): 1042–50

    Article  PubMed  CAS  Google Scholar 

  6. O’Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with “irreversible” emphysema. Eur Respir J 2001; 18: 914–20

    Article  PubMed  Google Scholar 

  7. O’Donnell DE, Lam W, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542–9

    PubMed  Google Scholar 

  8. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751–8

    Article  PubMed  CAS  Google Scholar 

  9. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773–8

    Article  PubMed  CAS  Google Scholar 

  10. Maesen FPV, Smeets JJ, Sledsen TJH, et al. Tiotropium bromide, a new long-acting anticholinergic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1506–13

    PubMed  CAS  Google Scholar 

  11. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of triotropium (Sprivia) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1136–42

    PubMed  CAS  Google Scholar 

  12. Casaburi R, Briggs Jr DD, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicentre trial. The US Tiotropium Study Group. Chest 2000; 118(5): 1294–302

    CAS  Google Scholar 

  13. Casaburi R, Mahler DA, Jones P, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–24

    Article  PubMed  CAS  Google Scholar 

  14. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator response. Chest 2003; 123: 1441–9

    Article  PubMed  CAS  Google Scholar 

  15. O’Donnell D, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004; 23(6): 832–40

    Article  PubMed  Google Scholar 

  16. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58(5): 399–404

    Article  PubMed  CAS  Google Scholar 

  17. Donohue FJ, van Noord JA, Bateman Ed, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122(1): 47–55

    Article  PubMed  CAS  Google Scholar 

  18. Vincken W, van Noord JA, Greefhorts APM, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J 2002, 216

  19. Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volume. Chest 2003; 124: 1743–8

    Article  PubMed  Google Scholar 

  20. Van Noord JA, Aumann J, Janssens E, et al. Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]. Am J Respir Crit Care Med 2003; 167: A320

    Google Scholar 

  21. Van Noord JA, Aumann J, Janssens E, et al. Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods [abstract]. Am J Respir Crit Care Med 2004; 167: A95

    Google Scholar 

  22. SPIRIVA© Prescribing information, Boehringer Ingelhiem International Pharma GMbH & Co., Ingelheim Germany [online]. Available from URL: http://www.spiriva.com [Accessed 2005, May 20]

  23. Türck D, Weber W, Sigmund R, et al. Pharmacokinetics of Intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol 2004; 44(2): 163–72

    Article  PubMed  Google Scholar 

  24. Anthonisen NR, Connett JR, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. JAMA 1994; 272: 1497–505

    Article  PubMed  CAS  Google Scholar 

  25. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 1982; 248: 1465–77

    Article  Google Scholar 

  26. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial. Ann Intern Med 1980; 93: 391–8

    Google Scholar 

  27. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; I: 681–6

    Google Scholar 

  28. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet 2000; 355: 362–8

    Article  PubMed  CAS  Google Scholar 

  29. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163: 585–91

    Article  PubMed  Google Scholar 

  30. Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994; 105: 1411–9

    Article  Google Scholar 

  31. Cazzola M, Marco FD, Santus P, et al. The pharmacologic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17: 35–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Dr O’Donnell has previously received research funding and speaker’s fees from Pfizer and Boehringer Ingelheim (Canada) Inc. No funding source played a role in the writing of this manuscript.

Author information

Authors and Affiliations

  1. Division of Respiratory and Critical Care Medicine, Queen’s University, 102 Stuart Street, Kingston, Ontario, K7L 2V6, Canada

    Farzad Saberi &  Denis E. O’Donnell

Authors
  1. Farzad Saberi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Denis E. O’Donnell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Denis E. O’Donnell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saberi, F., O’Donnell, D.E. The Role of Tiotropium Bromide, a Long-Acting Anticholinergic Bronchodilator, in the Management of COPD. Treat Respir Med 4, 275–281 (2005). https://doi.org/10.2165/00151829-200504040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151829-200504040-00005

Keywords

Search

Navigation